Industry Outlook
Paget’s disease treatment market is projected to grow at a CAGR of 3.4% during the forecast period from 2019 to 2027. Paget’s disease of bone affects the way that bone is renewed & repaired, during this process an uncontrolled level of bone generation occurs that results into an abnormal bone formation. The affected bone is weaker than normal and leads to a bend or deformity making that bone fragile. According to Arthritis Research UK, Paget’s disease is identified as the most common disease in UK and also observed in people from Southern & Western Europe including other countries such as Australia & New Zealand. In addition to that around 2 to 3 people in 100 and aged above 50 have Paget’s disease.
Market Synopsis
Get a sample copy for more information
"Bisphosphonate is the most preferred drug class against Paget’s disease and will maintain its dominance throughout the forecast period"
In 2018, Bisphosphonates were identified as the largest segment being the first choice of medical practitioners and increasing awareness related to Paget’s disease. Bisphosphonates are a vital class of drugs that tackles Paget’s disease by decreasing destruction of abnormal osteoclastic bone. In addition, bisphosphonates usually get settled in the bone; the advantage may last for several months or years and if given in the early stages, may prevent further complications.
Get a sample copy for more information
"Europe is the fastest growing market due to rising awareness in of Paget’s disease in medical practitioners and increasing diagnostic rates"
During the forecast period from 2019 to 2027, Europe expected to be the fastest growing Paget’s disease treatment market specifically due to increasing awareness in medical practitioners related to rare disorders, and developed healthcare infrastructure is supporting the rise in diagnosis rate. According to market experts, rising geriatric population in U.K. and highest prevalence rate of 4.6% makes it the most prevalent country globally. Thus, in the near future Europe expected to surpass North America and dominate the market during the forecast period from 2019 to 2027.
Get a sample copy for more information
Historical & Forecast Period
The Paget’s disease treatment market analyzed along with current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
This report covers the elaborative study of Paget’s disease treatment market covering market understandings and assumptions studied based on exhaustive qualitative and quantitative data collected through primary and secondary research. Industry sponsors through primary interviews have assisted to study and understand market dynamics such as opportunities, drivers, & challenges further segmented to region & respective countries. This report also includes an in-depth study of multiple segments of global Paget’s disease treatment such as the type of drug class, and geography. The report also provides an understanding related to competitive analysis of the vital companies present in Paget’s disease treatment market included with detail information such as current/future business strategies, financial data, & product portfolio.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
Type of Drug Class (2017–2027; US$ Mn)
• Bisphosphonates
o Zoledronic acid
o Pamidronate Disodium
o Etidronate
o Tiludronate
o Alendronate
o Risedronate
• Calcitonin Analogues (Salmon Calcitonin)
• Analgesics
• Calcium & Vitamin D Supplements
|
|
Geography Segment (2017–2027; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (Japan, China, Rest of APAC)
• Latin America (Brazil, Mexico, Rest of LATAM)
• Middle East and Africa (GCC, Rest of MEA)
|
The major companies currently available in the market analyzed based on recent market updates, product portfolio, financial data, and key strategies. This report also includes attractive investment proposition studied with the help of PESTEL analysis, which focuses on in-depth geographical research. Key companies present in the overall report are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Neopharma, Inc., Sanofi S.A., Allergan, Fresenius Kabi, Sun Pharmaceutical Industries, Ltd., and Mallinckrodt Pharmaceuticals among others.
Key questions answered in this report
- Which drug class type is in high demand to treat Paget’s disease & Why?
- What are the present market strategies & policies studied & applied by major market players & competitive landscape of the global Paget’s disease treatment market?
- Which are the important & imminent geographical markets (regions and countries) in Paget’s disease treatment market & Why?
- Which is the largest and fastest growing region globally in Paget’s disease treatment market?
- What will be the expected sales of drugs under pipeline in Paget’s disease treatment market?
